Ineffectiveness of Intermittent Hemodialysis in a Critically Ill COVID-19 Patient: A Case of Persistent Heparin-Induced Hyperkalemia.

Proceedings of the Human Factors and Ergonomics Society ... Annual Meeting. Human Factors and Ergonomics Society. Annual meeting Pub Date : 2022-03-04 eCollection Date: 2022-01-01 DOI:10.1155/2022/8613656

Yannick M Nlandu, Yannick M Engole, Marie-France I Mboliassa, Théodore-Junior M Sakaji, Patrick U Kobo, Patrick M Boloko, Pally K Mafuta, Joseph P Tsangu, Karel Van Echkout, Jean-Pierre M Kanku, Golan Kalifa, Rodolphe Ahmed, Justine B Bukabau

{"title":"Ineffectiveness of Intermittent Hemodialysis in a Critically Ill COVID-19 Patient: A Case of Persistent Heparin-Induced Hyperkalemia.","authors":"Yannick M Nlandu, Yannick M Engole, Marie-France I Mboliassa, Théodore-Junior M Sakaji, Patrick U Kobo, Patrick M Boloko, Pally K Mafuta, Joseph P Tsangu, Karel Van Echkout, Jean-Pierre M Kanku, Golan Kalifa, Rodolphe Ahmed, Justine B Bukabau","doi":"10.1155/2022/8613656","DOIUrl":null,"url":null,"abstract":"<p><p>Heparin is widely used in the intensive care unit despite the risk of bleeding it can cause. Although it is rarely reported, hyperkalemia is one of the side effects associated with heparin therapy (unfractionated or fractionated heparin). It would be secondary to hypoaldosteronism by blocking the biosynthesis of aldosterone in the adrenal gland and often appears in context of prolonged heparin therapy or inappropriate renin production in elderly, diabetic, and kidney insufficiency patients. We report a case of persistent hyperkalemia in a diabetic COVID-19 patient treated with curative heparin in the context of severe COVID-19.</p>","PeriodicalId":74544,"journal":{"name":"Proceedings of the Human Factors and Ergonomics Society ... Annual Meeting. Human Factors and Ergonomics Society. Annual meeting","volume":"61 1","pages":"8613656"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916869/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the Human Factors and Ergonomics Society ... Annual Meeting. Human Factors and Ergonomics Society. Annual meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/8613656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Heparin is widely used in the intensive care unit despite the risk of bleeding it can cause. Although it is rarely reported, hyperkalemia is one of the side effects associated with heparin therapy (unfractionated or fractionated heparin). It would be secondary to hypoaldosteronism by blocking the biosynthesis of aldosterone in the adrenal gland and often appears in context of prolonged heparin therapy or inappropriate renin production in elderly, diabetic, and kidney insufficiency patients. We report a case of persistent hyperkalemia in a diabetic COVID-19 patient treated with curative heparin in the context of severe COVID-19.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间歇性血液透析对 COVID-19 重症患者无效：一例持续性肝素诱发的高钾血症。

尽管肝素可能导致出血风险，但它仍被广泛用于重症监护病房。高钾血症是肝素治疗（非小份肝素或分馏肝素）的副作用之一，但很少有报道。高钾血症是通过阻断肾上腺醛固酮的生物合成而继发的低醛固酮血症，通常出现在长期肝素治疗或老年、糖尿病和肾功能不全患者肾素分泌不足的情况下。我们报告了一例糖尿病 COVID-19 患者在重度 COVID-19 的背景下接受肝素治疗后出现持续性高钾血症的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Proceedings of the Human Factors and Ergonomics Society ... Annual Meeting. Human Factors and Ergonomics Society. Annual meeting

自引率

0.00%

发文量